- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04506463
Efficacy and Safety of MM-II for Treatment of Knee Pain in Subjects With Symptomatic Knee Osteoarthritis
March 29, 2023 updated by: Sun Pharmaceutical Industries Limited
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Single-administration, Multiple-Dose Study to Demonstrate the Efficacy and Safety of MM-II for Treatment of Knee Pain in Subjects With Symptomatic Knee Osteoarthritis
This is a phase IIb, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of MM-II in subjects with symptomatic knee OA as compared to matching placebo.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
397
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Gandrup, Denmark, 9362
- Sunpharma site no. 02
-
Herlev, Denmark, 2730
- Sunpharma site no. 01
-
Vejle, Denmark, 7100
- Sunpharma site no. 03
-
-
-
-
-
Hong kong, Hong Kong, 00000
- Sunpharma site no. 14
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35209
- Sunpharma site no. 20
-
-
Arizona
-
Tempe, Arizona, United States, 85283
- Sunpharma site no. 11
-
-
California
-
Riverside, California, United States, 92503
- Sunpharma site no. 25
-
San Diego, California, United States, 92103
- Sunpharma site no. 26
-
-
Connecticut
-
Stamford, Connecticut, United States, 06905
- Sunpharma site no. 06
-
-
Florida
-
Lady Lake, Florida, United States, 32159
- Sunpharma site no. 10
-
Lake Worth, Florida, United States, 33461
- Sunpharma site no. 08
-
Maitland, Florida, United States, 32751
- Sunpharma site no. 13
-
Miami, Florida, United States, 33145
- Sunpharma site no. 22
-
Miami, Florida, United States, 33155
- Sunpharma Site no 27
-
Miami, Florida, United States, 33155
- Sunpharma site no. 12
-
Miami, Florida, United States, 33176
- SunPharma Site No 23
-
Sunrise, Florida, United States, 33351
- Sunpharma site no. 05
-
The Villages, Florida, United States, 32159
- Sunpharma site no. 04
-
-
Illinois
-
Flossmoor, Illinois, United States, 60422
- Sunpharma site no. 18
-
-
Missouri
-
Hazelwood, Missouri, United States, 63042
- Sunpharma site no. 07
-
-
New York
-
Williamsville, New York, United States, 14221
- Sunpharma site no. 17
-
-
Oklahoma
-
Edmond, Oklahoma, United States, 73013
- Sunpharma site no. 19
-
-
South Carolina
-
Charleston, South Carolina, United States, 29406
- Sunpharma site no. 09
-
Columbia, South Carolina, United States, 29206
- SunPharma Site No 24
-
Fort Mill, South Carolina, United States, 29707
- Sunpharma site no. 21
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years to 99 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subject is able to provide written consent, understand study requirements, is prepared to complete study procedures and is able to independently communicate meaningfully with study personnel
- Presence of index knee pain for at least 6 months prior to Screening
- Men or women ≥ 40 years of age at the time of Screening
- Radiographic evidence of knee Osteoarthritis
Exclusion Criteria:
- Pain in the contralateral knee with a severity of ≥ 30 mm on a 100 mm VAS
- Presence of ≥ 40 mm on a 100 mm VAS pain in any other joints
- Concomitant moderate or large size synovial fluid effusion of the index knee at Screening .
- Known diagnosis of infection in the index knee in the past five years prior to Screening
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm A
MM-II 1 ml
|
Intra-articular injection
|
Experimental: Arm B
MM-II 3 ml
|
Intra-articular injection
|
Experimental: Arm C
MM-II 6 ml
|
Intra-articular injection
|
Placebo Comparator: Arm 4
Placebo 1ml
|
Intra-articular injection
|
Placebo Comparator: Arm 5
Placebo 3ml
|
Intra-articular injection
|
Placebo Comparator: Arm 6
Placebo 6ml
|
Intra-articular injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline in Western Ontario and McMaster Universities osteoarthritis index (WOMAC) A pain score
Time Frame: Week 12
|
The pain score is based on a score of 0 to 4; the higher the score, the higher the amount of pain.
|
Week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Weekly average of daily knee pain scores by VAS
Time Frame: Week 26
|
Knee pain will be assessed on a score of 0 to 100; the lower on the scale, the less the amount of knee pain experienced.
|
Week 26
|
Weekly average of daily global pain scores by VAS
Time Frame: Week 26
|
Knee pain will be assessed on a score of 0 to 100; the lower on the scale, the less the amount of knee pain experienced.
|
Week 26
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 22, 2020
Primary Completion (Actual)
May 4, 2022
Study Completion (Actual)
August 10, 2022
Study Registration Dates
First Submitted
August 6, 2020
First Submitted That Met QC Criteria
August 6, 2020
First Posted (Actual)
August 10, 2020
Study Record Updates
Last Update Posted (Actual)
April 3, 2023
Last Update Submitted That Met QC Criteria
March 29, 2023
Last Verified
June 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CLR_17_17
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoarthritis of Knee
-
Joseph E. BroylesCompletedDegenerative Lesion of Articular Cartilage of Knee | Degeneration; Articular Cartilage, Knee | Unilateral Primary Osteoarthritis of Knee | Osteoarthritis Knee
-
CrystalGenomics, Inc.CompletedLocalized Primary Osteoarthritis of Hip | Localized Primary Osteoarthritis of KneeKorea, Republic of
-
zhoupingBeijing Friendship Hospital; Beijing Jishuitan HospitalUnknownOsteoarthritis Of KneeChina
-
Universidade Nova de LisboaHospital de Santa Maria, Portugal; NOVA Medical School; Hospital de Egas Moniz; Instituto de Medicina Molecular João Lobo Antunes and other collaboratorsUnknown
-
Ottawa Hospital Research InstituteCompleted
-
Hospices Civils de LyonSmith & Nephew, Inc.Completed
-
First Affiliated Hospital of Harbin Medical UniversityShanghai Baiying Medical Technology Co., Ltd.UnknownOsteoarthritis Of KneeChina
-
Stempeutics Research Pvt LtdStempeutics Research Malaysia SDN BHDCompleted
-
Government Medical College, BhavnagarCompletedOsteoarthritis of Knee JointIndia
-
GCS Ramsay Santé pour l'Enseignement et la RechercheRecruitingUnilateral Primary Osteoarthritis of KneeFrance
Clinical Trials on MM-II dose I
-
AtlasMedx, IncorporatedActive, not recruitingBreast Cancer | Pancreatic Cancer | Ovarian Cancer | Prostate Cancer | Homologous Recombination Deficiency | Advanced Malignant NeoplasmUnited States
-
Sun Pharma Advanced Research Company LimitedCompleted
-
Tyligand Bioscience (Shanghai) LimitedRecruitingHas a Pathologically Documented Unresectable Locally Advanced or Metastatic Solid Tumor or LymphomaChina
-
Scripps Clinic Cancer CenterThreshold PharmaceuticalsUnknownHepatocellular CarcinomaUnited States
-
Sun Pharmaceutical Industries LimitedTerminatedActive Ankylosing Spondylitis or Non-Radiographic Axial SpondyloarthritisUnited States, Hungary, Poland, Spain
-
Cellectar Biosciences, Inc.RecruitingMultiple Myeloma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Lymphoplasmacytic Lymphoma | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma | Central Nervous System LymphomaUnited States, Australia, Czechia, Greece, Israel, Brazil, Finland, France, Spain, Turkey, United Kingdom
-
University of California, DavisMars, Inc.Completed
-
Cairo UniversityRecruitingThe Influence of Vertical Implant Position on the Marginal Bone Loss in Thick Versus Thin Phenotype.Dental Implant | Esthetic Zone | Vertical Position | Bounded Edentulous AreaEgypt
-
University of South CarolinaMedical University of South Carolina; National Institute on Deafness and Other...Completed
-
Bharat Biotech International LimitedIndian Council of Medical ResearchCompletedCOVID-19 | SARS-CoV-2 InfectionIndia